New drug cocktail aims to slow advanced colon cancer in asian patients

NCT ID NCT04230187

Recruiting now Disease control Sponsor: Yanhong Deng Source: ClinicalTrials.gov ↗

First seen Mar 21, 2026 · Last updated May 07, 2026 · Updated 7 times

Summary

This phase 3 trial tests whether a stronger chemotherapy combination (mFOLFOXIRI) plus bevacizumab works better than a standard combo (mFOLFOX-6) plus bevacizumab for people with advanced colorectal cancer that cannot be removed by surgery. The study focuses on Asian patients, who often have more side effects from standard treatments. About 528 participants will be followed to see how long the cancer stays under control and if the stronger combo improves survival or allows more surgeries.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Gastrointestinal Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, 510655, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

COLORECTAL CANCER